Blog

Drew Moghanaki: A look back at arguably the most important phase III RCT ever completed in the history of oncology

Photo taken from Drew Moghanaki/X

Jun 2, 2024, 12:03

Drew Moghanaki: A look back at arguably the most important phase III RCT ever completed in the history of oncology

Drew Moghanaki shared on X:

“Here is a look back at arguably the most important phase III RCT ever completed in the history of oncology.

It’s known as the ‘Bonadonna Study‘ that American surgeons of the time refused to support, requiring
the National Cancer Institute to sponsor it in Italy. The results shepherded a new era of MDT collaboration, which has saved innumerable lives ever since.

Here are Giannia Bonadonna and Umberto Vernoesi, who led the study together. To them, we are forever grateful.

Drew Moghanaki: A look back at arguably the most important phase III RCT ever completed in the history of oncology

Knowing about this amazing study and similar political obstacles overcome over the past century to move the field of surgical oncology forward is crucial to fully appreciate the field of cancer research as we know it today.

This is why I believe the following two books are must-reads for all clinicians and scientists involved with cancer research. I trust Mark Lewis would agree!”

Drew Moghanaki: A look back at arguably the most important phase III RCT ever completed in the history of oncology

Source: Drew Moghanaki/X

Drew Moghanaki, a Professor and Chief of Thoracic Oncology at the Department of Radiation Oncology, UCLA. He holds the Stanley Iezman and Nancy Stark Endowed Chair in Thoracic Radiation Oncology Research at the same university. He specializes in treating lung cancer and other thoracic malignancies, focusing on advanced radiation therapy techniques like stereotactic body radiation therapy (SBRT), magnetic resonance-guided radiation therapy (MRgRT), and intensity-modulated radiation therapy (IMRT).